BridgeBio Pharma Inc
BBIO: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| SWf | LOCK|SD | LOCK|WB&x&L |
BridgeBio Earnings: Attruby Growth and Pipeline Updates Support Long-Term Outlook
BridgeBio reported $353 million in sales, up roughly 193% year over year, and ahead of FactSet consensus. Attruby (for ATTR-CM) sales contributed $253 million, up roughly 14% sequentially, reflecting physician uptake and new-patient adoption. Shares are up roughly 6% on Oct. 30.
